Clinical Trials Browser

Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03322865 2025-04-04

Obinutuzumab in Marginal Zone Lymphoma

Phase 2 Active not recruiting

56 enrolled

Lymphoid

Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Phase 1 Completed

11 enrolled 16 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06793189 2025-01-27

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Phase 2 Not yet recruiting

145 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06566807 2024-08-22

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

Phase 2 Recruiting

51 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06513234 2024-07-22

Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

Phase 2 Recruiting

45 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06454968 2024-06-18

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Phase 2 Recruiting

45 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT03010358 2023-08-08

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Phase 1/2 Completed

24 enrolled 16 charts

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT05846750 2023-07-19

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Phase 2 Recruiting

59 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT03276468 2023-01-10

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Phase 2 Completed

136 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04796922 2022-07-18

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Phase 3 Withdrawn

Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

Clinical Trials

MAHOGANY

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

ARIADNE

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Obinutuzumab in Marginal Zone Lymphoma

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)